Doug Witt | CEO
Unison Medicines
Doug Witt is the CEO and cofounder of Unison Medicines, a discovery-stage pharmaceutical company focused on solving the Anti-Microbial Resistance crisis. Unison discovers novel small molecules which block bacterial DNA damage repair and associated stress responses. Previously Doug worked at Amgen as an Early Operations Leader for an early stage asset and a chemical engineer where he led upstream large molecule manufacturing engineering through multiple product launches and FDA approvals. Prior to Amgen, Doug served as a submarine officer in the US Navy, where he led robotics technology development, and held key leadership roles during five deployments aboard the USS ALABAMA BLUE, a high-performing $5B nuclear-powered ballistic missile submarine carrying $2B in weapons and 150 sailors. Doug is a graduate of the Leaders for Global Operations program at MIT, earning an MBA and an engineering masters (focus on genetics). He studied chemistry and Chinese at Stanford as an undergraduate.
Appearances:
Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 12:00
Panel: Navigating the landscape - Strategies for early-stage developmental funding
The panel will address current strategies for early-stage funding chosen by the different panelists and give examples of successful company founding and funding. It will also address gaps and issues with the current funding landscape and within and between the supporting partners, and finally on novel business strategies chosen by the panelists to cope with those gaps. The addressed audience are start-ups, scientists and business developers in the AMR field and those planning to build a start-up, organizations supporting start-ups and everyone interested in early-stage development in the field of AMR.
Sponsored by LifeArc
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events